Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Sep 1;91(1):87-96.
doi: 10.1016/j.bcp.2014.06.010. Epub 2014 Jun 19.

Presynaptic GABAB autoreceptor regulation of nicotinic acetylcholine receptor mediated [(3)H]-GABA release from mouse synaptosomes

Affiliations

Presynaptic GABAB autoreceptor regulation of nicotinic acetylcholine receptor mediated [(3)H]-GABA release from mouse synaptosomes

Tristan D McClure-Begley et al. Biochem Pharmacol. .

Abstract

Activation of nicotinic acetylcholine receptors (nAChRs) can elicit neurotransmitter release from presynaptic nerve terminals. Mechanisms contributing to cell-and-terminal specific regulation of nAChR-mediated neurotransmitter exocytosis are not fully understood. The experiments discussed here examine how activation of GABAB auto- and hetero-receptors suppress nAChR-mediated release of [(3)H]-GABA and [(3)H]-dopamine ((3)H-DA) from mouse striatal synaptosomes. Activation of presynaptic GABAB receptors with (R)-baclofen decreased both [(3)H]-GABA and [(3)H]-DA release evoked by potassium depolarization. However, when nAChRs were activated with ACh to evoke neurotransmitter release, (R)-baclofen had no effect on [(3)H]-DA release, but potently inhibited ACh-evoked [(3)H]-GABA release. Inhibition of nAChR-evoked [(3)H]-GABA release by (R)-baclofen was time sensitive and the effect was lost after prolonged exposure to the GABAB agonist. The early inhibitory effect of GABAB activation on ACh-evoked [(3)H]-GABA release was partially attenuated by antagonists of the phosphatase, calcineurin. Furthermore, antagonists of protein kinase C (PKC) prevented the time-dependent loss of the inhibitory (R)-baclofen effect on [(3)H]-GABA release. These results suggest that α4β2*-nAChRs present on GABAergic nerve terminals in the striatum are subject to functional regulation by GABAB autoreceptors that is apparently cell-type specific, since it is absent from DAergic striatal nerve terminals. In addition, the functional modulation of α4β2*-type nAChRs on striatal GABAergic nerve terminals by GABAB autoreceptor activation is time-sensitive and appears to involve opposing actions of calcineurin and PKC.

Keywords: Calcineurin; GABA(B) receptor; Neurotransmitter release; Nicotinic receptor; Protein kinase C.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Application (10 minutes) of (R)-baclofen elicits a concentration-dependent decrease in the amount of [3H]-GABA released by depolarization with 10mM K+. (*)-denotes p<0.05, Dunnett’s post-hoc analysis.
Figure 2
Figure 2
Effect of 100μM (R)-baclofen on [3H]-GABA (a) and [3H]-DA release (b) evoked by increasing concentrations of K+. Neurotransmitter release was measured under control conditions (black bars) and with a 30 second exposure to 100μM (R)-baclofen (gray bars). Inhibition of both [3H]-GABA and [3H]-DA release by (R)-baclofen is apparently voltage dependent as strong depolarization (20mM K+) overcomes inhibition of neurotransmitter release. (*)-denotes p<0.05, student’s t-test.
Figure 3
Figure 3
Inhibition of [3H]-GABA release evoked by 10μM ACh with 100μM (R)-baclofen is time-dependent. The inhibitory effect of (R)-baclofen decreases over time with constant drug application, with a t1/2 of 3.3 minutes. (*)-denotes p<0.05, Dunnett’s post-hoc analysis.
Figure 4
Figure 4
Application of (R)-baclofen inhibits [3H]-GABA release evoked by 10μM ACh in a concentration-dependent fashion when applied 30 seconds prior to stimulation with ACh. (*)-denotes p<0.05, Dunnett’s post-hoc analysis.
Figure 5
Figure 5
Effect of 100μM (R)-baclofen on ACh-evoked [3H]-GABA (a) and [3H]-DA (b) release. (a) [3H]-GABA release evoked by ACh under control conditions (black circles) and with a 30 second exposure to 100μM (R)-baclofen (white circles). Pretreatment with 100μM (R)-baclofen significantly decreased ACh-evoked [3H]-GABA release, and had no appreciable effect on ACh-evoked [3H]-DA release.
Figure 6
Figure 6
(a) 4μM CGP54626 completely eliminates the inhibitory effect of 100μM (R)-baclofen on [3H]-GABA release evoked by 30μM ACh from striatal synaptosomes, but has no effect on ACh-evoked [3H]-GABA release on its own (b).
Figure 7
Figure 7
100μM (R)-baclofen inhibits [3H]-GABA release evoked by ACh from synaptosomes prepared from interpeduncular nucleus (a), midbrain (b), cortex (c), and hippocampus (d). (*)-denotes p<0.05, 2-way ANOVA.
Figure 8
Figure 8
Inhibition of calcineurin with 100nM cypermethrin does not affect (R)-baclofen inhibition of [3H]-GABA release evoked by 10mM K+ (a), but incompletely prevents (R)-baclofen inhibition of [3H]-GABA release evoked by ACh (b). An additional calcineurin antagonist (FK506; 1μM) also prevents (R)-baclofen inhibition of ACh-evoked [3H]-GABA release to a similar extent as 100nM cypermethrin (c). (*)-denotes p<0.05, student’s t-test, (***)-denotes p=0.0003, paired t-test).
Figure 9
Figure 9
Loss of (R)-baclofen inhibition of nAChR agonist-evoked [3H]-GABA release after 5 minutes of continuous (R)-baclofen (100μM) exposure is prevented by antagonism of PKC with chelerythrine (10μM, 5 minutes prior to (R)-baclofen application). (*)-denotes p<0.05, student’s t-test.

Similar articles

Cited by

References

    1. Gotti C, Clementi F, Fornari A, Gaimarri A, Guiducci S, Manfredi I, Moretti M, Pedrazzi P, Pucci L, Zoli M. Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem Pharmacol. 2009 Oct 1;78(7):703–11. - PubMed
    1. Lukas RJ, Changeux JP, Le Novère N, Albuquerque EX, Balfour DJ, Berg DK, Bertrand D, Chiappinelli VA, Clarke PB, Collins AC, Dani JA, Grady SR, Kellar KJ, Lindstrom JM, Marks MJ, Quik M, Taylor PW, Wonnacott S. International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev. 1999;51(2):397–401. - PubMed
    1. Flores CM, Rogers SW, Pabreza LA, Wolfe BB, Kellar KJ. A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol. 1992;41(1):31–7. - PubMed
    1. Wu J, Lukas RJ. Naturally-expressed nicotinic acetylcholine receptor subtypes. Biochem Pharmacol. 2011;82(8):800–7. - PMC - PubMed
    1. Orr-Urtreger A, Göldner FM, Saeki M, Lorenzo I, Goldberg L, De Biasi M, Dani JA, Patrick JW, Beaudet AL. Mice deficient in the alpha7 neuronal nicotinic acetylcholine receptor lack alpha-bungarotoxin binding sites and hippocampal fast nicotinic currents. J Neurosci. 1997 Dec 1;17(23):9165–71. - PMC - PubMed

Publication types

MeSH terms